Biochemia medicaPub Date : 2023-10-15DOI: 10.11613/BM.2023.030703
Ye Hua, Ting Jiang, Jiangyi Feng, Mi Zou
{"title":"Negligible effect of vitamin D supplementation on exacerbation in patients with chronic obstructive pulmonary disease: meta-analysis.","authors":"Ye Hua, Ting Jiang, Jiangyi Feng, Mi Zou","doi":"10.11613/BM.2023.030703","DOIUrl":"10.11613/BM.2023.030703","url":null,"abstract":"<p><strong>Introduction: </strong>The focus of this meta-analysis was how vitamin D supplementation influences exacerbations in patients with chronic obstructive pulmonary disease (COPD) and vitamin D deficiency (VDD).</p><p><strong>Materials and methods: </strong>Cochrane Library, Web of Science, Embase, and PubMed databases have been systematically searched in an attempt to collect randomized controlled trials related to vitamin D supplementation in COPD patients with VDD published in English available by July 2022. Primary outcome indicators included the mean number of exacerbation and rate of exacerbation. Secondary outcome indicators included forced expiratory volume in the first second (FEV1), FEV1/forced vital capacity (FVC) ratio, and serum 25-hydroxyvitamin D (25(OH)D) concentration.</p><p><strong>Results: </strong>Five studies involving 522 COPD patients with VDD (defined as 25(OH)D < 50 nmol/L) were included, among them 61 were severely deficient in vitamin D (25(OH)D < 25 nmol/L). The results showed that vitamin D supplementation did not decrease the mean number of exacerbation (standardized mean difference (SMD): - 0.10, 95% CI: - 0.29 to 0.09) and the rate of exacerbation (relative risk (RR): 0.89, 95% CI: 0.76 to 1.04, P = 0.179). Also, its effect on FEV1 (SMD: - 0.06, 95% CI: - 0.30 to 0.17) and FEV1/FVC (SMD: -0.10, 95% CI: - 0.48 to 0.27) remained negligible. However, it could increase the serum 25(OH)D concentration (SMD: 2.44, 95 CI%: 2.20 to 2.68, P < 0.001).</p><p><strong>Conclusions: </strong>The effects of vitamin D supplementation on decreasing exacerbation and improving pulmonary function were not significant.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"33 3","pages":"030703"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biochemia medicaPub Date : 2023-10-15DOI: 10.11613/BM.2023.031201
Marija Gomerčić Palčić, Hana Matijaca, Ivan Kruljac, Lucija Vusić, Vedran Hostić, Luka Vrbanić, Fanika Mrsić, Radovan Zrilić, Ivana Ćelap, Petar Gaćina
{"title":"Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience.","authors":"Marija Gomerčić Palčić, Hana Matijaca, Ivan Kruljac, Lucija Vusić, Vedran Hostić, Luka Vrbanić, Fanika Mrsić, Radovan Zrilić, Ivana Ćelap, Petar Gaćina","doi":"10.11613/BM.2023.031201","DOIUrl":"10.11613/BM.2023.031201","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.11613/BM.2023.020704.].</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"33 3","pages":"031201"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biochemia medicaPub Date : 2023-10-15DOI: 10.11613/BM.2023.030505
Tze Ping Loh, Brian R Cooke, Thi Chi Mai Tran, Corey Markus, Rosita Zakaria, Chung Shun Ho, Elvar Theodorsson, Ronda F Greaves
{"title":"The LEAP checklist for laboratory evaluation and analytical performance characteristics reporting of clinical measurement procedures.","authors":"Tze Ping Loh, Brian R Cooke, Thi Chi Mai Tran, Corey Markus, Rosita Zakaria, Chung Shun Ho, Elvar Theodorsson, Ronda F Greaves","doi":"10.11613/BM.2023.030505","DOIUrl":"10.11613/BM.2023.030505","url":null,"abstract":"<p><p>Reporting a measurement procedure and its analytical performance following method evaluation in a peer-reviewed journal is an important means for clinical laboratory practitioners to share their findings. It also represents an important source of evidence base to help others make informed decisions about their practice. At present, there are significant variations in the information reported in laboratory medicine journal publications describing the analytical performance of measurement procedures. These variations also challenge authors, readers, reviewers, and editors in deciding the quality of a submitted manuscript. The International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Method Evaluation Protocols (IFCC WG-MEP) developed a checklist and recommends its adoption to enable a consistent approach to reporting method evaluation and analytical performance characteristics of measurement procedures in laboratory medicine journals. It is envisioned that the Laboratory Evaluation and Analytical Performance Characteristics (LEAP) checklist will improve the standardisation of journal publications describing method evaluation and analytical performance characteristics, improving the quality of the evidence base that is relied upon by practitioners.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"33 3","pages":"030505"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biochemia medicaPub Date : 2023-10-15DOI: 10.11613/BM.2023.030705
Tomáš Šálek, Vladimír Soška, Marek Budina, Marek Vecka, Veronika Šálková, Michal Vrablík
{"title":"Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia.","authors":"Tomáš Šálek, Vladimír Soška, Marek Budina, Marek Vecka, Veronika Šálková, Michal Vrablík","doi":"10.11613/BM.2023.030705","DOIUrl":"10.11613/BM.2023.030705","url":null,"abstract":"<p><strong>Introduction: </strong>This survey aims to assess the implementation of recommendations from the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) by clinical biochemistry laboratories in Czechia and Slovakia in their policies for reporting low-density lipoprotein cholesterol (LDL-C) concentrations.</p><p><strong>Materials and methods: </strong>The web-based survey was distributed to all 383 Czech and Slovak clinical biochemistry laboratories that measure lipids by external quality assessment provider SEKK. A total of 17 single-answer questions were included. The questionnaire was focused on the detection and decision points in familial hypercholesterolemia (FH). All survey answers were taken into account. The laboratories followed the EFLM and EAS guidelines when they reported an interpretative comment considering FH diagnosis in adults.</p><p><strong>Results: </strong>A total of 203 (53%) laboratories answered. Only 5% of laboratories added interpretative comments considering FH diagnosis when LDL-C concentrations are above 5.0 mmol/L in adults, and 3% of laboratories added interpretative comments considering FH diagnosis when LDL-C concentrations are above 4.0 mmol/L in children. Only 7% of laboratories reported goals for all cardiovascular risk categories (low, moderate, high, very high). Non-HDL cholesterol concentrations were calculated by 74% of responders. A significant number (51%) of participants did not measure apolipoprotein B, and 59% of laboratories did not measure lipoprotein(a).</p><p><strong>Conclusions: </strong>Only a small portion of laboratories from Czechia and Slovakia reported high LDL-C results with interpretative comments considering FH diagnosis in adults, the laboratories did not follow the guidelines.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"33 3","pages":"030705"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Biochemia medicaPub Date : 2023-10-15DOI: 10.11613/BM.2023.030801
Nadia Sadriani, Ferdy Royland Marpaung
{"title":"Undetectable high-performance liquid chromatography haemoglobin A1c on variant haemoglobin E phenotype: a case report.","authors":"Nadia Sadriani, Ferdy Royland Marpaung","doi":"10.11613/BM.2023.030801","DOIUrl":"10.11613/BM.2023.030801","url":null,"abstract":"<p><p>The gold standard for long-term monitoring of diabetic patients is glycated haemoglobin (HbA1c), which is routinely tested for glycaemic control. Furthermore, the National glycohemoglobin standardization program (NGSP) has designated high-performance liquid chromatography (HPLC) as the reference method for HbA1c measurement. A woman from the Sumba tribe, Indonesia, aged 52, visited the Internal Medicine Clinic for a routine check-up. She had been taking diabetic and hypertension medicines on a regular basis for over 10 years. The HPLC procedure yielded \"no result\" for the patient's HbA1c assessment and there was no peak on the HPLC graphic. However, there was a discrepancy between the data history of HbA1c measured by turbidimetric method (average of 51 mmol/mol, reference range < 48 mmol/mol), fasting blood glucose (average of 7.7 mmol/L, reference range < 7.0 mmol/L) and 2-hour plasma glucose (average of 13 mmol/L, reference range < 11.1 mmol/L). Glycated albumin was 3.1 mmol/L (reference range 1.8-2.4 mmol/L). Haemoglobin electrophoresis identified homozygote haemoglobinopathy E (HbE). Patients with haemoglobin variants are proposed to utilize glycated albumin.</p>","PeriodicalId":94370,"journal":{"name":"Biochemia medica","volume":"33 3","pages":"030801"},"PeriodicalIF":0.0,"publicationDate":"2023-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}